Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

NCT: NCT06569082 · RECRUITING

NCT IDNCT06569082
StatusRECRUITING
Start Date2024-10-31
Completion2035-08
SponsorNYU Langone Health (OTHER)
First posted
Last updated

Brief Summary

The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.

Frequently Asked Questions

What is CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure?

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure is a clinical trial registered under NCT06569082. Current status: RECRUITING.

What is the status of NCT06569082?

The current status of NCT06569082 (CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure) is: RECRUITING.

When did CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure start?

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure started on 2024-10-31.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑